Qiagen (NYSE:QGEN)‘s stock had its “neutral” rating reissued by investment analysts at Jefferies Financial Group in a research report issued on Monday.
Other analysts have also issued reports about the stock. Commerzbank reissued a “buy” rating on shares of Qiagen in a research note on Monday, September 17th. Deutsche Bank set a $44.00 target price on shares of Qiagen and gave the company a “buy” rating in a research note on Friday, October 5th. BidaskClub raised shares of Qiagen from a “sell” rating to a “hold” rating in a research note on Friday, November 2nd. Morgan Stanley boosted their target price on shares of Qiagen from $39.00 to $41.00 and gave the company an “overweight” rating in a research note on Wednesday, October 31st. Finally, Barclays reaffirmed a “buy” rating on shares of Qiagen in a research note on Tuesday, October 30th. Seven analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $40.67.
NYSE QGEN opened at $36.48 on Monday. The company has a quick ratio of 1.25, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. The firm has a market cap of $8.26 billion, a price-to-earnings ratio of 28.72, a PEG ratio of 2.16 and a beta of 0.92. Qiagen has a 52 week low of $31.01 and a 52 week high of $39.45.
A number of large investors have recently added to or reduced their stakes in the stock. Morgan Stanley raised its holdings in Qiagen by 16.3% in the third quarter. Morgan Stanley now owns 1,468,052 shares of the company’s stock worth $55,611,000 after purchasing an additional 205,698 shares in the last quarter. Vanguard Group Inc raised its holdings in Qiagen by 2.0% in the third quarter. Vanguard Group Inc now owns 6,627,163 shares of the company’s stock worth $251,037,000 after purchasing an additional 128,125 shares in the last quarter. Finally, State of Alaska Department of Revenue raised its holdings in Qiagen by 2.0% in the fourth quarter. State of Alaska Department of Revenue now owns 23,547 shares of the company’s stock worth $811,000 after purchasing an additional 463 shares in the last quarter. 62.73% of the stock is owned by institutional investors.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.